Since the PD-L1 inhibitors atezolizumab and durvalumab were approved by the US Food and Drug Administration (FDA) for the first-line treatment of patients with ES-SCLC, the era of immunotherapy for ES-SCLC has begun. The gene discussed is CD274; the disease is small cell lung carcinoma.